Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms. (Q47704805)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975426%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

title

Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975426%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975426%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

G Garrido

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975426%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

A Rabasa

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975426%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

C Garrido

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975426%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

A López

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975426%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

L Chao

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975426%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

F Garrido

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975426%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

L E Fernández

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975426%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

B Sánchez

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975426%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

language of work or name

English

0 references

publication date

26 August 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975426%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975426%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975426%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

issue

24

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975426%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

page(s)

3129-3139

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23975426%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/onc.2013.288

8 March 2020

exact match

0 references

cites work

The ERBB network: at last, cancer therapy meets systems biology.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

The future of antibodies as cancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

EGFR-Targeting as a Biological Therapy: Understanding Nimotuzumab's Clinical Effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Cetuximab ± chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Cetuximab-mediated tumor regression depends on innate and adaptive immune responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

7A7 MAb: a new tool for the pre-clinical evaluation of EGFR-based therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Structure of the Fab fragment of the anti-murine EGFR antibody 7A7 and exploration of its receptor binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

T cells are crucial for the anti-metastatic effect of anti-epidermal growth factor receptor antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Induction of immunogenic apoptosis by blockade of epidermal growth factor receptor activation with a specific antibody.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Inhibition of PI-3K restores nuclear p27Kip1 expression in a mouse model of Kras-driven lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

The transforming potential of the c-erbB-2 protein is regulated by its autophosphorylation at the carboxyl-terminal domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

The role of Src in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Immunosuppressive strategies that are mediated by tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

IFN inducibility of major histocompatibility antigens in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Implications for immunosurveillance of altered HLA class I phenotypes in human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

MHC class I antigens and immune surveillance in transformed cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Unresponsiveness to interferon associated with STAT1 protein deficiency in a gastric adenocarcinoma cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Decreased STAT1 expression by promoter methylation in squamous cell carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

The subunits MECL-1 and LMP2 are mutually required for incorporation into the 20S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

FHIT-proteasome degradation caused by mitogenic stimulation of the EGF receptor family in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

MHC class I molecules act as tumor suppressor genes regulating the cell cycle gene expression, invasion and intrinsic tumorigenicity of melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

The differential expression of H-2K versus H-2D antigens, distinguishing high-metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Alterations of HLA class I expression in human melanoma xenografts in immunodeficient mice occur frequently and are associated with higher tumorigenicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Loss of IFN gamma receptor is an independent prognostic factor in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288

Immunization by gamma-IFN-treated B16-F10.9 melanoma cells protects against metastatic spread of the parental tumor.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2013.288